Decheng Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Decheng Capital LLC
CRD #293073
SEC #801-118587
CIK #0002010850
AUM 2,728.2 M (2026-03-31)
Employees 23 (57% Investors, 0% Brokers)
Fees
Minimum
Phone650-382-5514
Address3000 Sand Hill Road
Menlo Park, CA 94025
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
3.02.41.81.20.60.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Fees and Compensation

A.       As an SEC registered investment adviser which provides services to private funds that exclusively
accept “Qualified Purchasers,” as defined by the Investment Company Act, DC Global is not required to
disclose its specific compensation terms in this Sub-Item.

B.        The Funds pay the Firm an annual management fee, which is prorated and directly deducted from the
Funds each quarter. The calculation of the management fee for Decheng Capital China Life Sciences USD
Fund I, L.P, Decheng Capital China Life Sciences USD Fund II, L.P, Decheng Capital China Life Sciences
USD Fund III, L.P, Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Life Sciences
Fund V, L.P., Decheng Capital Global Life Sciences Fund V-A, L.P., and Decheng Capital Global Life Sciences
Fund V-B, L.P. are (i) based on a percentage of commitments to the fund from the first year to the fifth year
of investment, (ii) based on a percentage of cost of remaining investments for the sixth through tenth years,
and (iii) reduced to zero after ten years. For Decheng Global Healthcare Fund (Master), LP, management fees
are based on the percent of account balance, which includes valuation of the portfolio.

C.       The Funds bear all costs of organization and operation, including all trading costs and expenses (e.g.,
brokerage commissions, transaction fees, spreads, custody, taxes, interest and borrowing costs, clearing, and
settlement charges), and all ongoing legal, accounting, tax, bookkeeping, professional, expert and consulting
fees and expenses (including the fees and expenses of the directors, the administrator, attorneys and compliance
consultants (with certain limitation) for the General Partners and DC Global, research consultants, research-
related fees and expenses (including certain travel expenses), portfolio and risk management systems, and
quotation services and related equipment), and each Fund’s proportionate share of its costs and expenses. The
Funds also pay some or all of these expenses on their behalves and allocate them among the relevant capital
accounts.

D.       The General Partners and DC Global generally bear their own operating, general, administrative and
overhead costs and expenses, other than the expenses described above. More information related to expense
allocations can be found in the Funds’ Governing Documents.

E.       The management fee is paid in advance. With respect to the venture capital funds, carried interest is
paid to General Partners in arrears upon the disposition of a portfolio asset. Prospectively, funds with a public
market mandate will pay to their General Partner or DC Global an annual performance-based fee in arrears,
subject to any relevant high-water marks and hurdle rates of return.

F.       Except as otherwise disclosed, neither the Firm nor any of its supervised persons receive, directly or
indirectly, any compensation from the sale of securities or other investment products.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Types of Clients

        The Firm provides investment advisory services to pooled investment vehicles that are excepted from
the definition of investment company pursuant to Section 3(c)(7) under the Investment Company Act. As
disclosed in other areas of this Brochure, investment in the Funds is only available to Qualified Purchasers and
the minimum initial commitment is $5 million.
Sector Form 13F Holdings Value ($M)
CG Oncology Inc 431.2
Panacea Acquisition Corp 111.3
Upstream Bio Inc 24.5
Aclaris Therapeutics Inc 15.2
Aardvark Therapeutics Inc 14.8
Lyell Immunopharma Inc 13.9
Newamsterdam Pharma Co NV 10.4
Arcus Biosciences Inc 10.3
Revolution Medicines Inc 9.1
Equillium Inc 8.9
View All
Holdings by Sector ($M)
80064048032016002024202520262027
Type Form D Funds Date Sold AUM
VC Decheng Capital Global Life Sciences Fund V-A LP [2025-03-31] 452.0 M 32.9 M
Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose
VC Decheng Capital Global Life Sciences Fund V-B LP [2025-03-31] 452.0 M 22.0 M
Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose
VC Decheng Capital Global Life Sciences Fund V LP [2025-03-31] 452.0 M 449.3 M
Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose
HF Decheng Capital Global Healthcare Fund Master LP [2021-03-31] 139.0 M 228.2 M
Filed 2025-10-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
VC Decheng Capital Global Life Sciences Fund IV LP [2021-03-31] 825.3 M
Offered $650,000,000 · Filed 2020-12-15 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $650,000,000 · Duration One year or less · Revenue Decline to Disclose
VC Decheng Capital China Life Sciences USD Fund III LP [2018-07-19] 625.9 M
Offered $450,000,000 · Filed 2018-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $450,000,000 · Duration One year or less · Revenue Decline to Disclose
VC Decheng Capital China Life Sciences USD Fund II LP [2018-07-19] 480.6 M
Offered $250,000,000 · Filed 2015-08-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $250,000,000 · Duration One year or less · Revenue Decline to Disclose
VC Decheng Capital China Life Sciences USD Fund I LP [2018-07-19] 123.0 M 78.9 M
Offered $125,000,000 · Filed 2013-06-05 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining $1,998,247 · Duration More than one year · Revenue Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 10 2.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 10 2.7
By Discretionary
Discretionary 10 2.7
Non-Discretionary 0 0.0
Total 10 2.7
By Non-United States Persons
Non-United States Persons 2.6
United States Persons 0.2
Total 10 2.7
Form D Directors Role # Filings # Firms 2011 - 2026
Xiangmin Cui Director, Executive Officer, Promoter 14 2
Bay City Capital LLC Director 2 2
Decheng Capital SV LLC Executive Officer 2 2
Decheng Capital Global Healthcare GP LLC Executive Officer 2 2
Decheng Capital Management IV Cayman LLC Promoter 1 1
Yuheng Qiu Director 1 1
DT Capital Management Company Limited Director 1 1
Fengying Yu Promoter 1 1
Decheng Capital China Management I Cayman LLC Promoter 1 1
Xiangmin Min Director 1 1
Decheng Capital Management II Cayman LLC Promoter 1 1
Decheng Capital Management III Cayman LLC Promoter 1 1
Decheng Capital Management V Cayman LLC Promoter 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0002010850]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
Comparable Firms State AUM
Pointer Management LLC
TN 2,790.9 M
Serone Capital Management LLP
2,731.1 M
Sound Point Commercial Real Estate Finance LLC
NY 2,723.4 M
Mangrove Partners IM LLC
CT 2,705.9 M
1Sharpe Capital LLC
CA 2,700.3 M
Hook Mill Capital Partners LP
NY 2,698.0 M
Advanced Portfolio Management LLC
NY 2,697.1 M
Gobi Capital LLC
CA 2,689.4 M
Cadian Capital Management LP
NY 2,680.0 M
Eversept Partners LP
NY 2,651.0 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com